Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 01/31/25 | EFFECT | Notice of Effectiveness |
|
1 | |
| 01/31/25 | EFFECT | Notice of Effectiveness |
|
1 | |
| 01/31/25 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
14 | |
| 01/31/25 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
9 | |
| 01/30/25 | S-1/A | General form of registration statement for all companies including face-amount certificate companies |
|
16 | |
| 01/30/25 | S-1/A | General form of registration statement for all companies including face-amount certificate companies |
|
22 | |
| 01/28/25 | CORRESP | Correspondence |
|
1 | |
| 01/28/25 | CORRESP | Correspondence |
|
1 | |
| 01/28/25 | UPLOAD | SEC-generated letter |
|
1 | |
| 01/28/25 | UPLOAD | SEC-generated letter |
|
1 |
